Cambrex

Cambrex is a prominent global contract development and manufacturing organization (CDMO) established in 1981. The company specializes in providing comprehensive drug substance, drug product, and analytical services throughout the entire pharmaceutical lifecycle. Serving both branded and generic markets, Cambrex acts as a critical partner for pharmaceutical companies requiring high-quality API development and finished dosage form manufacturing. Their technical expertise spans continuous flow, controlled substances, and solid-state science, ensuring robust support for complex therapeutic development.

Operating with a workforce of 1,000-5,000 employees, Cambrex maintains a significant operational footprint across 11 global locations. The organization delivers specialized capabilities including material characterization, stability storage, and the production of highly potent APIs. Their manufacturing infrastructure supports a diverse array of dosage forms, such as oral solids, semi-solids, liquids, and specialty formats like modified-release, fixed-dose combinations, and sterile ointments. This technical breadth allows Cambrex to address intricate manufacturing challenges for global clients in North America and Europe.

In the competitive CDMO landscape, Cambrex distinguishes itself through decades of experience and a commitment to innovation in drug commercialization. The company competes with major industry players like Lonza, Catalent, and Patheon Pharma Services, leveraging its deep scientific expertise to maintain market relevance. Meet Cambrex's team to learn about their leadership and the organizational structure driving these technical advancements. By focusing on high-value services and rigorous quality standards, Cambrex continues to support the evolving needs of the global healthcare sector.